Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AEF 0117

Next Previous
Drug Profile

AEF 0117

Alternative Names: AEF-0117

Latest Information Update: 08 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aelis Farma
  • Developer Aelis Farma; Columbia University; National Institute of Drug Abuse; New York State Psychiatric Institute
  • Class Drug withdrawal therapies
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Substance-related disorders

Most Recent Events

  • 22 Jul 2024 Aelis Farma completes the phase IIb SICA 2 trial for substance related disorders in USA (PO) (NCT05322941)
  • 29 Apr 2024 Aelis Farma in collaboration with National Institute on Drug Abuse (NIDA) plans a phase I trial in Substance-related disorders (In volunteers) in June 2024 (PO) (NCT06395688)
  • 26 Jun 2023 Aelis Farma terminates a phase I trial in Substance-related disorders (In volunteers, In adults) in USA (PO) due to a research hold of the institution. However, the study will not continue as the sample size of patients collected prior to the pause allowed for adequate data analysis of the study endpoints (NCT05451017)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top